Jo-Anne Wilson
Associate Professor

Email: jo-anne.wilson@dal.ca
Mailing Address:
5968 College Street
PO Box 15000
College of Pharmacy
Dalhousie University
Halifax, NS
B3H 4R2
Research Topics:PO Box 15000
College of Pharmacy
Dalhousie University
Halifax, NS
B3H 4R2
- Diabetic Kidney Disease
- Prescribing and desprescribing
- Chronic Kidney Disease
- Pharmacokinetics
- Anemia Management
Education
- BSc(Pharm) (Dalhousie)
- CSHP Accredited Hospital Pharmacy Residency (ACPR) (Dalhousie)
- PharmD (Medical University South Carolina)
- Masters of Adult Education (St. Frances Xavier University)
Research interests
Dr. Jo-Anne Wilson’s primary research focuses on medication management optimization and safety, prescribing and deprescribing initiatives, models of care or program development, implementation and evaluation, creation of clinical information technology tools and the evaluation of the pharmacokinetics and pharmacodynamics of drug therapies in patients with chronic kidney disease including dialysis.
Selected awards and honours
- 2022 National Journal Award, Hamilton, ON Canadian Association of Nephrology Nurses and Technologists
- 2022 Making Waves Innovator Award, Halifax, NS Nova Scotia Health Research and Innovation
- 2018 Innovative Leading Practice Award, Health Standards Organization, Ottawa, ON Accreditation Canada
Selected publications
- Wilson JA, Ratajczak N, Halliday K, Battistella M, Naylor H, Sheffield M, Marin JG, Pitman J, Kennie-Kaulback N, Trenaman S, Gillis L. Medications for community pharmacists to dose adjust or avoid to enhance prescribing safety in individuals with advanced chronic kidney disease: a scoping review and modified Delphi. BMC Nephrol. 2024 Oct 29:25(1):386.
- Wilson JA, Ptman J, Marin J, Wazny LD, Battistella M, Review ofthe top nephrology studies of 2020-2023. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 2024;157(4):174-180.
- Tran J, Shaffelburg C, Phelan E, Neville H, Lively A, Tennankore K, More K, Poyah P, Soroka S, Harpell D, Wilson J. Community pharmacists’ perspectives of enablers and barriers to kidney function assessment and dose adjustment in advanced chronic kidney disease: A qualitative study using the theoretical domains framework. Accepted Can Pharm J 2023.
- Cho T, Battistella, M, Patrick N, Lefebvre, M, Desjarlais, A, McCann D, Waldvogel B, Tonelli M, Garg A, Wilson J, Beaulieu M, Marin J, Orsulak C, Talson M, Sharma M, Feldberg, J, Bohm, C, Battistella, M. Development and validation of patient education tools for deprescribing in patients on hemodialysis. Can J Kidney Health and Dis 2023; 10: 1-12.
- England E, Sheffield M, Poyah P, Clark D, Wilson J. Ferric derisomaltose evaluation in non-dialysis dependent chronic kidney disease and peritoneal dialysis patients. Can J Hosp Pharm 2023;76(2):94-101.